Page last updated: 2024-11-02

piribedil and Leukemia, Myeloid, Acute

piribedil has been researched along with Leukemia, Myeloid, Acute in 1 studies

Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.

Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, X1
Zheng, X1
Yang, H1
Yan, J1
Fu, X1
Wei, R1
Xu, X1
Zhang, Z1
Yu, A1
Zhou, K1
Ding, J1
Geng, M1
Huang, X1

Other Studies

1 other study available for piribedil and Leukemia, Myeloid, Acute

ArticleYear
Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
    Cancer letters, 2018, 09-01, Volume: 431

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Cell Proliferation; Dop

2018